Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vaccine ; 36(40): 6017-6021, 2018 09 25.
Artículo en Inglés | MEDLINE | ID: mdl-30172633

RESUMEN

Clostridium difficile flagellin FliC is a highly immunogenic pathogen-associated molecular pattern playing a key role in C. difficile pathogenesis and gut colonization. Here, we designed an oral vaccine against C. difficile with FliC encapsulated into pectin beads for colonic release. Bead stability and FliC retention was confirmed in vitro using simulated intestinal media (SIM), while bead degradation and FliC release was observed upon incubation in simulated colonic media (SCM). The importance of FliC encapsulation into pectin beads for protection against C. difficile was assessed in a vaccination assay using a lethal hamster model of C. difficile infection. Three groups of hamsters orally received either FliC-loaded beads or unloaded beads in gastro-resistant capsule to limit gastric degradation or free FliC. Two other groups were immunized with free FliC, one intra-rectally and the other intra-peritoneally. Hamsters were then challenged with a lethal dose of C. difficile VPI 10463. Fifty percent of hamsters orally immunized with FliC-loaded beads survived whereas all hamsters orally immunized with free FliC died within 7 days post challenge. No significant protection was observed in the other groups. Only intra-peritoneally immunized hamsters presented anti-FliC IgG antibodies in sera after immunizations. These results suggest that an oral immunization with FliC-loaded beads probably induced a mucosal immune response, therefore providing a protective effect. This study confirms the importance of FliC encapsulation into pectin beads for a protective oral vaccine against C. difficile.


Asunto(s)
Vacunas Bacterianas/inmunología , Infecciones por Clostridium/prevención & control , Flagelina/inmunología , Inmunidad Mucosa , Pectinas/administración & dosificación , Administración Oral , Animales , Proteínas Bacterianas/inmunología , Vacunas Bacterianas/química , Cápsulas , Clostridioides difficile , Colon/inmunología , Colon/microbiología , Cricetinae , Modelos Animales de Enfermedad , Femenino , Inmunoglobulina G/sangre , Microesferas , Vacunación/métodos
2.
Pathol Biol (Paris) ; 55(8-9): 412-7, 2007 Nov.
Artículo en Francés | MEDLINE | ID: mdl-17905539

RESUMEN

AIM OF THE STUDY: Our objective is to determine in vitro efficiency of moxifloxacin (MXF) alone or in combination with cefotaxime (CTX) on Group B streptococcus (GBS). MATERIALS AND METHODS: For 21 strains of GBS isolated from newborn invasive infections (6 meningitis and 15 bacteraemia), the bacterial growth in Mueller Hinton broth with MXF and/or CTX leaded to the determination of MIC and MBC, the determination of tolerance for CTX and the evaluation of the bacteriostatic action of these antibiotics combination by calculating the FIC index. Time-kill studies were conducted for MXF and CTX alone or in combination for the first four hours, with concentrations likely reached in CSF. RESULTS: Study of GBS growth with crossed concentrations of MXF and CTX showed no resistant strains, no tolerant strains, and no antagonism between MXF and CTX. Killing curves demonstrated that MXF is ten-fold more active than CTX in the first four hours. DISCUSSION: MXF is an interesting antibiotic for its good activity on the GBS, suggesting that MXF is a good candidate for further evaluation in GBS meningitis in animal model.


Asunto(s)
Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Cefotaxima/uso terapéutico , Quinolinas/uso terapéutico , Infecciones Estreptocócicas/diagnóstico , Streptococcus agalactiae/efectos de los fármacos , Bacteriemia/diagnóstico , Bacteriemia/microbiología , Quimioterapia Combinada , Fluoroquinolonas , Humanos , Recién Nacido , Meningitis Bacterianas/diagnóstico , Meningitis Bacterianas/microbiología , Pruebas de Sensibilidad Microbiana , Moxifloxacino , Serotipificación , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus agalactiae/clasificación , Streptococcus agalactiae/aislamiento & purificación
3.
Bull Cancer ; 72(4): 298-302, 1985.
Artículo en Francés | MEDLINE | ID: mdl-4063539

RESUMEN

Incidence rates of the cancer registry of the department of Calvados were compared, by site and by age group, with those obtained from the cancer registry of the comprehensive cancer center in Caen, concerning the population of the department of Calvados. In males, these rates are approximately similar for head and neck sites; for the hospital registry they are 50% of those recorded by the population registry for lung cancer, and 30% for prostatic cancer. In females, the all-sites rates are nearly identical for the youngest age groups and 50% for the older. They are not significantly different for digestive cancer, and 75% for cervix and breast cancer. The incidence rates of both registries were compared with mortality rates. They indicate mortality rates which appear relatively high for the pancreas, and they show imprecisions for the uterus and head and neck (pharynx-larynx) sites.


Asunto(s)
Hospitales , Neoplasias/epidemiología , Sistema de Registros , Adulto , Factores de Edad , Anciano , Neoplasias de la Mama/epidemiología , Neoplasias del Sistema Digestivo/epidemiología , Femenino , Francia , Neoplasias de Cabeza y Cuello/epidemiología , Humanos , Neoplasias Pulmonares/epidemiología , Masculino , Persona de Mediana Edad , Neoplasias/mortalidad , Neoplasias de Oído, Nariz y Garganta/epidemiología , Neoplasias Pancreáticas/epidemiología , Neoplasias de la Próstata/epidemiología , Sistema de Registros/normas , Factores Sexuales , Neoplasias del Cuello Uterino/epidemiología , Neoplasias Uterinas/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA